The FDA’s “Roadmap to Reducing Animal Testing” signals a shift: NAMs will play a central role in nonclinical safety and toxicology assessments, with the explicit goal that animal studies become the exception rather than the rule.  Your programs, protocols, and technology stacks may need to reflect this shift now from animal-heavy workflows to human-relevant in vitro/in silico models.